Recent research has linked clozapine, a powerful medication for schizophrenia, to an increased risk of mortality associated with pneumonia and severe gastrointestinal complications.
Clozapine is the only drug in the United States approved to treat “treatment-resistant schizophrenia,” which affects one in five schizophrenic patients. It was removed from global markets in the 1970s due to its association with dangerously low white blood cell counts in 2 percent of users.
